All In Biotech

Drug Trial Radar · NCT02024412

Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC

The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Nov 2013

Primary completion

Dec 2016

Study completion Dec 2017

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 31, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The morbidity of colorectal cancer(CRC) is 10%~15% in China.mFolfox6 has become one of the standard regimes for metastatic colorectal cancer (mCRC). Neutropenia and oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in discontinue of chemotherapy, especially for patients suffered from heavily acute neurotoxicity. Monosialotetrahexosylganglioside is a component of membrane of nerve cells. Previous phase II clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(OIN). But it did not certificated by phase III trial. Investigators designed the phase III trial to investigate the effect and safety of monosialotetrahexosylganglioside Sodium Injection for prevention OIN at colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • monosialotetrahexosylganglioside SodiumDrug

    it is a component extract from pig's brain,shenjie is the brand name

  • placeboOther

    saline of the same appearance as monosialotetrahexosylganglioside Sodium

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicityTime frame: From the first day of chemotherapy to 12 months after study or until one week before the patients receive second-line chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.